Registry following adults with lupus under rheumatology care
Collects routine visit data from adults with systemic lupus erythematosus and their doctors.
Plain-language title generated from the registry record
Registry title: CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry
Key facts
- Where
- Waltham, United StatesSee the site
Where in United States
- CorEvitasWaltham, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CorEvitas
- Trial code
- NCT06804057
- Record updated
- 6 February 2026
- Original description
Prospective, observational registry for subjects with SLE under the care of a rheumatology provider. Longitudinal data are collected from both subjects and their treating rheumatology provider during routine clinical encounters using a structured and standardized data collection method.Read full original descriptionShow less
CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry
Prospective, observational registry for subjects with SLE under the care of a rheumatology provider. Longitudinal data are collected from both subjects and their treating rheumatology provider during routine clinical encounters using a structured and standardized data collection method.
Inclusion: To be eligible to participate in this registry, an individual must meet all the following criteria:; Has been diagnosed with SLE by a rheumatologist or a qualified rheumatology practitioner; Is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted at the time of enrollment; Willing and able to provide informed consent; Willing and able to provide Personally Identifiable Information (full legal name, sex at birth, date of birth, and home address zip/postal code at a minimum) if required based on registry location and applicable laws and regulations; In addition, subjects must meet at least one of the following criteria:; New diagnosis of SLE (=<12 months) from registry enrollment, OR; Initiation of a biologic or immunosuppressant for the treatment of SLE at registry enrollment, OR; Lupus Nephritis (LN; class III-V) diagnosed within 2 years of registry enrollment.
Exclusion: Is participating in a double-blind clinical trial for a SLE drug; Subjects participating in any non-blinded trial for any indication, with the exception of non-blinded CAR-T or other cell/gene therapies for the treatment of SLE; An individual who meets any of the following criteria will be excluded from participation in the registry:.